Focal therapy treats prostate cancers without surgery and its potential side effects. It follows a fundraising campaign which ...

All men at high risk of prostate cancer should be offered checks even if it costs the NHS more to deliver it ... early improves the odds of successful treatment. The Daily Mail is campaigning ...

A pioneering non-invasive treatment for prostate cancer will be launched after a successful fundraising campaign. More than ...

This follows the initial licence for treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in 2020. Following entry into a commercial agreement with Bayer ...

We know that if you're black or from a working class area, you're more likely to get an incurable prostate cancer diagnosis and less likely to get the best treatments on the NHS. 'We're reaching ...

People with prostate cancer often face the unenviable task of deciding between treatments with side-effects that can profoundly affect their lives. They rely on health professionals to support them ...

The first targeted treatment for the most common form of bladder cancer has been approved for NHS use. The National Institute of Health ... READ MORE: New at-home spit test may work better than ...

and treatments. Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust trialled their new DNA test which looks for genetic variants linked to prostate ...

The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect recurrence in ... imaging and support diagnostic pathways within the NHS.” ...

The saliva test, which can be done at home, was proven to be more accurate at detecting prostate cancer than existing tests offered by the NHS in a ... without needing treatment has meant that ...

Routine PSA testing is not currently offered on the NHS ... the offer. Prostate cancer was detected in 187 men and, of these, 103 had cancer that was deemed to be "higher risk", so treatment ...

had prostate cancer classified as intermediate or higher risk according to the 2024 National Comprehensive Cancer Network (NCCN) criteria, so treatment was indicated; cancer would not have been ...